A team of researchers from APL and the Johns Hopkins Bloomberg School of Public Health is developing next-generation brain organoid platforms to better understand the effects of mild blast-induced ...

Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year ...

To report issues, contact Bausch + Lomb Customer Service at 1-800-338-2020, option 1, or submit a report to FDA’s MedWatch program. Saleen Martin is a reporter on USA TODAY's NOW team.

But it reiterated a view a full separation from Bausch Health Companies is still the goal. Bausch Health Companies owns 88.4% of Bausch and Lomb. Saunders believes interested buyers undervalued the ...

Bausch and Lomb said earlier this month that it had explored taking the company private with a third-party buyer. No deal was reached, as a consortium of private equity firms including TPG (TPG ...

After selling off Bausch + Lomb, Saunders took over as CEO at Forest Laboratories, where it took him five months to execute its sale to Actavis for $25 billion in February of 2014. He was tapped ...

However, ex-Bausch + Lomb's contribution, the figure falls to $1.3bn, made up of a $642m contribution from the Salix segment — sales of gastrointestinal products, $291m from the International ...

Bausch + Lomb recently announced the U.S. launch of Opal, a digital e-commerce marketplace designed to streamline ordering of contact lenses and other products, according to a press release ...

Products are available through a customizable catalog on Opal, including Bausch + Lomb contact lens brands such as Bausch + Lomb INFUSE ®, Bausch + Lomb ULTRA ® and Biotrue ® ONEday.